Galapagos
UK green lights Gilead Sciences, Galapagos ulcerative colitis drug
Joy Persaud
Galapagos, Gilead, market access, MHRA, pharma
0 Comment
News/ News/ Sales and Marketing
Galapagos’ long-serving CEO Onno van de Stolpe to retire
Phil Taylor
Galapagos, Gilead Sciences, senior management
0 Comment
Trials leave Galapagos’ SIK programme looking under the weather
Phil Taylor
Galapagos, Gilead Sciences, psoriasis, Rheumatoid arthritis, SIK inhibitor, ulcerative colitis
0 Comment
Market Access/ Podcast/ Video/ Views & Analysis/ Views and analysis
Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast
mike.smith@pharmaphorum.com
Galapagos, HTA, Michael Smyth, podcast, rna
0 Comment
Gilead/Galapagos alliance hit again as IPF drug is binned
Phil Taylor
fibrosis, Galapagos, Gilead Sciences, idiopathic pulmonary fibrosis, partnership, respiratory disease
0 Comment
NICE backs broad use for Gilead/Galapagos arthritis pill Jyseleca
Phil Taylor
filgotinib, Galapagos, Gilead, HEOR, NHS, NICE, Rheumatoid arthritis
0 Comment
News/ News/ Sales and Marketing
Gilead’s rheumatoid arthritis pill approved in Japan
Richard Staines
Eisai, filgotinib, Galapagos, Gilead, Jyseleca, Rheumatoid arthritis
0 Comment
News/ News/ R&D/ Top stories
Analysts question Gilead’s commitment to arthritis drug after FDA setback
Richard Staines
Galapagos, Gilead, inflammatory diseases, Rheumatoid arthritis, ulcerative colitis
0 Comment